Positron Emission Tomography News and Research

RSS

SNM commends FDA Advisory Committee recommendation for florbetapir approval

The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.

25 Jan 2011

MedImmune announces MEDI-573 preclinical results against many solid tumors

MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors.

21 Jan 2011

No robust conclusions possible on advantages or disadvantages of PET

Malignant gliomas are fast-growing brain tumours with poor prospects of recovery depending on disease stage. Experts hope that the examination of patients by means of positron emission tomography (PET) is more helpful in the choice of the right treatment than other procedures. In a final report the German Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated the benefit of PET in the detection of recurrences. According to this report, no robust conclusions are possible on the advantages or disadvantages of PET.

20 Jan 2011

Bupropion and varenicline help curb cigarette craving

The smoking cessation medications bupropion and varenicline may both be associated with changes in the way the brain reacts to smoking cues, making it easier for patients to resist cravings, according to two reports posted online today that will appear in the May print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Jan 2011

18F-FDG PET scans help evaluate cognitive dysfunction of pediatric fever-induced epilepsy

Sudden, catastrophic childhood epilepsy is a parent's worst nightmare, especially in the case of fever-induced refractory epileptic encephalopathy in school-age children (FIRES). While not much is known about the condition, new research published in the January issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans can offer an evaluation of cognitive dysfunction of FIRES, its evolution and further prognosis.

4 Jan 2011

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

The American Thoracic Society has released a new official clinical policy statement on the treatment of fungal infections in adult pulmonary and critical care patients.

4 Jan 2011

Positron granted U.S. patents for quantum photodetectors

Positron Corporation, a leading molecular imaging company specializing in the field of nuclear cardiology, today announced it has received two U.S. patents for its proprietary quantum photodetectors.

24 Dec 2010

Results of proteomics study performed utilizing plasma samples from ADNI now available

The Foundation for the National Institutes of Health's Biomarkers Consortium announced today that the results of a proteomics study performed utilizing plasma samples from the Alzheimer's Disease Neuroimaging Initiative are ready to be shared with scientists worldwide for further analysis.

9 Dec 2010

PET/CT scan predicts, detects local recurrence after radiofrequency ablation

A study published in the December issue of The Journal of Nuclear Medicine identified positron emission tomography/computed tomography (PET/CT) scans as a potentially useful tool for predicting local recurrence in lung cancer patients treated with radiofrequency ablation (RFA). RFA, which uses localized thermal energy to kill cancer cells, is increasingly used as an alternative treatment for patients unable to undergo surgery or other therapies to treat lung cancer.

7 Dec 2010

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that initial safety and efficacy data from its ongoing Phase II Study with resminostat, a pan-Histone Deacetylase (HDAC) Inhibitor, in relapsed/refractory Hodgkin Lymphoma (HL) patients after high dose chemotherapy and autologous hematopoietic stem cell transplantation will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, USA.

1 Dec 2010

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Neuroscientists using a new brain imaging technique could see an investigational drug for Parkinson's disease get into a patient's brain and affect blood flow in several key structures, an indicator the drug may be effective.

1 Dec 2010

Philips ushers new era in radiology science with Imaging 2.0 technology at RSNA annual meeting

This year at the 96th annual meeting of the Radiological Society of North America (RSNA) in Chicago, Royal Philips Electronics is ushering in a new era in radiology science with Imaging 2.0, a concept fueled by integration of technology, clinician and patient.

From Philips Healthcare 29 Nov 2010

Eckert & Ziegler enters exclusive sales agreement with Zyklotron for Fluorodeoxyglucose

Eckert & Ziegler Strahlen- und Medizintechnik AG, a company specializing in special compounds for the diagnosis and treatment of cancer, via its subsidiary company Eckert & Ziegler f-con Deutschland GmbH closed an exclusive sales agreement with the Karlsruhe-based ZAG Zyklotron AG for the regular delivery of Fluorodeoxyglucose (18F) (FDG). FDG is used in the context of the so called Positron Emission Tomography (PET) for the safe and quick recognition of even the smallest tumour foci.

23 Nov 2010

Researchers to discuss latest advances in Alzheimer's research

Today, America's biopharmaceutical research companies highlighted the 98 new medicines in the pipeline for Alzheimer's disease and other dementias, either in clinical trials or awaiting FDA review.

20 Nov 2010

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

At the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 28 - December 2 in Chicago, Siemens Healthcare (Booth #822, East Building/Lakeside Center, Hall D) will unveil the Biograph mMR, the world's first integrated whole-body molecular Magnetic Resonance (MR) system with simultaneous data acquisition technology, currently undergoing clinical use testing.

20 Nov 2010

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

BioInvent International AB today announces IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation in the blood vessel walls. BI-204 is being co-developed with Genentech for secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS).

10 Nov 2010

New radiotracer application may advance understanding of estrogen-related diseases

A study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory has demonstrated that a molecule "tagged" with a radioactive form of carbon can be used to image aromatase, an enzyme responsible for the production of estrogen, in the human brain. The research, published in the November issue of Synapse, also uncovered that the regions of the brain where aromatase is concentrated may be unique to humans.

4 Nov 2010

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine.

4 Nov 2010

Study reveals a potential target for treating brain trauma

Brain damage continues to develop and evolve for months after a traumatic brain injury (TBI), revealing a potential target for treatments to improve brain trauma, new research led by the University of Melbourne, Australia has found.

3 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

Positron Emission Tomography News and Research

SNM commends FDA Advisory Committee recommendation for florbetapir approval

MedImmune announces MEDI-573 preclinical results against many solid tumors

No robust conclusions possible on advantages or disadvantages of PET

Bupropion and varenicline help curb cigarette craving

18F-FDG PET scans help evaluate cognitive dysfunction of pediatric fever-induced epilepsy

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

Positron granted U.S. patents for quantum photodetectors

Results of proteomics study performed utilizing plasma samples from ADNI now available

PET/CT scan predicts, detects local recurrence after radiofrequency ablation

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Philips ushers new era in radiology science with Imaging 2.0 technology at RSNA annual meeting

Eckert & Ziegler enters exclusive sales agreement with Zyklotron for Fluorodeoxyglucose

Researchers to discuss latest advances in Alzheimer's research

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

New radiotracer application may advance understanding of estrogen-related diseases

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

Study reveals a potential target for treating brain trauma

Immunomedics product candidates, technologies receive recognition from QTDP program

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News